Whitebox Advisors LLC Has $29.37 Million Holdings in Grifols, S.A. (NASDAQ:GRFS)

Whitebox Advisors LLC decreased its holdings in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,947,631 shares of the biotechnology company's stock after selling 273,852 shares during the quarter. Grifols comprises approximately 0.9% of Whitebox Advisors LLC's holdings, making the stock its 29th largest position. Whitebox Advisors LLC owned about 0.57% of Grifols worth $29,370,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GRFS. Jane Street Group LLC bought a new stake in shares of Grifols in the third quarter valued at approximately $363,000. Barclays PLC boosted its holdings in Grifols by 381.2% in the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock valued at $5,261,000 after purchasing an additional 469,401 shares during the period. Geode Capital Management LLC grew its position in Grifols by 56.1% in the 3rd quarter. Geode Capital Management LLC now owns 110,532 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 39,733 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Grifols during the 3rd quarter worth about $147,000. Finally, JPMorgan Chase & Co. raised its position in shares of Grifols by 144.0% during the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock valued at $17,782,000 after buying an additional 1,181,959 shares during the last quarter.

Grifols Price Performance

Shares of NASDAQ GRFS traded down $0.33 during mid-day trading on Tuesday, hitting $7.13. 451,081 shares of the stock were exchanged, compared to its average volume of 1,190,621. The company has a market cap of $4.90 billion, a P/E ratio of 6.11 and a beta of 0.44. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96. The stock's fifty day simple moving average is $7.43 and its two-hundred day simple moving average is $7.69.

Analyst Ratings Changes

Separately, Morgan Stanley initiated coverage on Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.